Can Patients Afford the Cost of Treatment for Multidrug-resistant Tuberculosis in Ethiopia?

Journal Article
  • David Collins
  • Demissew Beyene
  • Yared Tedla
  • Hiwot Mesfin
  • Ermias Diro
International Journal of Tuberculosis and Lung Disease
Aug. 2018; vol. 22 (8): pp. 905-911(7). DOI: https://doi.org/10.5588/ijtld.17.0837.

ABSTRACT

Setting

Ethiopia has a high prevalence of tuberculosis (TB) and is one of the countries with the highest burden of multidrug-resistant TB (MDR-TB).

Objective

To understand the costs that patients incur in obtaining diagnosis and treatment for MDR-TB.

Design

In March 2013, interviews were conducted with 169 MDR-TB patients at three hospitals in Ethiopia to identify the cost to patients and the impact on employment and family income.

Results

The average MDR-TB patient incurred a total cost of US$1378, which represented 25 months of a mid-treatment household income of US$54. The impact on the patient's employment and on overall patient and family income was generally catastrophic: 74% of all respondents reported losing their jobs, 66% of patients lost household income, and household income was reduced by 38%. To help cover the costs, 38% of patients sold some type of property, while 7% leased out property and 41% took out loans, any of which could jeopardize their future financial situation even further.

Conclusion

Despite services being officially free of charge, most patients incurred catastrophic costs and suffered significant income loss as a result of obtaining diagnosis and treatment for MDR-TB.